Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
Express Scripts
Harvard Business School
Citi
Colorcon
McKesson
Moodys
AstraZeneca
Baxter

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,360,800

« Back to Dashboard

Summary for Patent: 5,360,800
Title: Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
Abstract:The invention relates to tricyclic lactams of the general formula (I) ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenyl C.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl or phenoxymethyl, one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl C.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkhyl group; n represents 2 or 3; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.
Inventor(s): Coates; Ian H. (Hertford, GB2), North; Peter C. (Royston, GB2), Oxford; Alexander W. (Royston, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:07/741,570
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 5,360,800

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,360,800

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8720695Sep 03, 1987
United Kingdom8819382Aug 15, 1988

International Patents Family Members for US Patent 5,360,800

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
United Kingdom 8820736 ➤ Try a Free Trial
United Kingdom 8819382 ➤ Try a Free Trial
United Kingdom 8720695 ➤ Try a Free Trial
United Kingdom 2209335 ➤ Try a Free Trial
Germany 3851597 ➤ Try a Free Trial
Finland 89484 ➤ Try a Free Trial
Denmark 490188 ➤ Try a Free Trial
Denmark 170506 ➤ Try a Free Trial
European Patent Office 0306323 ➤ Try a Free Trial
European Patent Office 0356098 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
Daiichi Sankyo
US Department of Justice
AstraZeneca
McKinsey
Citi
Dow
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot